Capmatinib and Tepotinib are two FDA-approved Tyrosine Kinase Inhibitors (TKIs) that are used to treat non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping [42,43]. The gene discussed is MET; the disease is non-small cell lung carcinoma.